1. Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis
Report Details:
Published:November 2012
No. of Pages: 46
Price: Single User License – US$6995
Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, Masitinib (Rheumatoid
Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the
November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting
approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s
SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to
dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once
they enter the market.
AB Science is developing a novel oral c-Kit inhibitor (tyrosine kinase inhibitor) known as masitinib,
or AB101. Inhibition of the c-Kit pathway leads to a decrease in histamine levels, mast cells, and
IL-4 production, thus decreasing the allergic response. This antineoplastic drug is currently in an
international, multicenter, randomized, double-blind, placebo-controlled, three-parallel group
Phase IIb/III clinical trial for RA in the US and Czech Republic.
Scope
- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment
guidelines as well as an overview on the competitive landscape.
- Detailed information on Masitinib including product description, safety and efficacy profiles as
well as a SWOT analysis.
- Sales forecast for Masitinib for the top eight countries from 2011 to 2022.
- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and
Australia.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return

2. - Stay ahead of the competition by understanding the changing competitive landscape for
rheumatoid arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising
sales potential
- Make more informed business decisions from insightful and in-depth analysis of Masitinib
performance
- Obtain sales forecast for Masitinib from 2011 to 2022 in (the US, France, Germany, the UK, Italy,
Spain, Japan and Australia)
Get your copy of this report @
http://www.reportsnreports.com/reports/213182-masitinib-rheumatoid-arthritis-forecast-and-market-analysis.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
3 Disease Overview 9
3.1 Etiology and Pathophysiology 9
3.1.1 Etiology 9
3.1.2 Pathophysiology 9
3.1.3 Prognosis 12
3.1.4 Quality of Life 12
3.2 Symptoms 13
4 Disease Management 14
4.1 Overview 14
4.2 Diagnosis 14
4.3 Treatment 17
5 Competitive Assessment 21
5.1 Overview 21
5.2 Strategic Competitor Assessment 21
6 Opportunity and Unmet Need 23
6.1 Overview 23
6.2 Unmet Needs 24
6.2.1 More rheumatologists in the field and physician knowledge of the disease 24
6.2.2 More cost-effective therapies through oral formulation and biosimilars 24
6.2.3 The development of predictive tests and discovery of biomarkers 24
6.2.4 The discovery of curative therapies 25
6.2.5 Improved drug safety and efficacy profiles 25
6.3 Gap Analysis 26

3. 6.4 Opportunities 27
6.4.1 Predictive tools for diagnosis and treatment 27
6.4.2 Target specificity 27
7 Pipeline Assessment 28
7.1 Overview 28
7.2 Promising Drugs in Clinical Development 29
8 Masitinib (AB101) 31
8.1 Overview 31
8.2 Efficacy 32
8.3 Safety 33
8.4 Dosing and Formulation 33
8.5 Potential Clinical Positioning 33
8.6 Potential Commercial Positioning 33
8.7 Pricing and Reimbursement 34
8.8 SWOT Analysis 34
8.9 Forecast 35
9 Appendix 36
9.1 Abbreviations 36
9.2 Bibliography 38
9.3 Methodology 41
9.4 Forecasting Methodology 41
9.4.1 Diagnosed Rheumatoid Arthritis Patients 41
9.4.2 Percent Drug-treated Patients 41
9.4.3 General Pricing Assumptions 42
9.4.4 Pricing of Pipeline agents 43
9.5 Physicians and Specialists Included in this Study 43
9.6 Primary Research - Prescriber Survey 44
9.7 About the Authors 44
9.7.1 Analysts 44
9.7.2 Global Head of Healthcare 45
9.8 About GlobalData 46
9.9 Contact Us 46
9.10 Disclaimer 46
1.1 List of Tables
Table 1: Symptoms of Rheumatoid Arthritis 13
Table 2: Treatment Guidelines for Rheumatoid Arthritis 17
Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 20
Table 4: Treatment Guidelines for Rheumatoid Arthritis 22
Table 5: Overall Unmet Needs - Current Level of Attainment 23
Table 6: Clinical Unmet Needs - Gap Analysis, 2012 26
Table 7: Rheumatoid Arthritis - Phase Pipeline, 2012 29

4. Table 8: Comparison of Therapeutic Classes in Development for RA, 2012 30
Table 9: Product Profile - Masitinib 31
Table 10: ACR Responses for Masitinib in the ITT Population (12 Weeks) 32
Table 11: ACR Responses for Masitinib in the ITT Population (12-82 Weeks) 32
Table 12: Masitinib SWOT Analysis, 2012 34
Table 13: Global Sales Forecasts ($m) for Masitinib 35
Table 14: Physicians Surveyed, By Country 44
1.2 List of Figures
Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis 9
Figure 2: Rheumatoid Arthritis Biologic Drug Targets 11
Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point
System 16
Figure 4: Severity of Rheumatoid Arthritis 16
Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations*
19
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022 29
Contact: sales@reportsandreports.com for more information.